Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Carbone says choosing between dervatremi and ipinevo is barely a choice because the dervatremi data are weaker, especially in squamous disease where the same signal is absent. Based on current evidence, he personally uses the ipinevo combination rather than dervatremi in his clinic for first-line NSCLC.

Related Insights

The CheckMate 9LA regimen provides exceptional benefit to PD-L1 negative and squamous histology NSCLC patients. This is significant because these subgroups often respond poorly to other immunotherapy combinations, with Dr. Carbone noting some trials where the control arm outperformed pembrolizumab in these patients.

Carbone points to Keynote 407 five-year data where PD-L1-negative squamous tumors did so poorly that more control-arm patients were alive than treated patients. In his practice, he uses the 9LA dual immunotherapy regimen in that setting for those patients because long-term survival with chemoimmunotherapy is unimpressive.

Experts favor a Nivolumab plus Ipilimumab (NIVO+EP) combination for newly diagnosed, MSI-high, stage IV gastroesophageal cancer patients who can tolerate it. This approach avoids chemotherapy and yields high, sustained response rates, including potential for complete pathologic responses in metastatic settings.

Carbone says Checkmate 227 used dual immunotherapy without chemotherapy and had almost exactly the same efficacy, including in PD-L1-negative subsets. He questions whether adding chemotherapy, especially four cycles, adds much benefit, and he notes that patients in his experience often like having only two cycles.

In an ongoing confirmatory trial, investigators rarely re-challenge PD-1 refractory patients with another PD-1 inhibitor alone. This real-world clinical consensus, viewing the practice as futile, provides strong practical evidence that the nivolumab in the combination isn't the sole driver of efficacy, supporting RP1's significant contribution.

Despite major advances in immunotherapy, patient selection remains crude compared to targeted therapies. PD-L1 is still the primary, yet imperfect, biomarker used. Dr. Carbone highlights an urgent need to develop better predictive biomarkers to customize immunotherapy regimens, as is standard for targeted agents.

Data shows that patients who permanently stopped ipilimumab due to immune-related side effects still had exceptionally good outcomes. This gives clinicians confidence to manage toxicity by discontinuing the CTLA-4 inhibitor portion of the regimen while continuing nivolumab, without fearing a loss of efficacy.

For resectable, driver-negative NSCLC, clinicians must choose from four Category 1 chemo-immunotherapy options without direct comparative data. This includes one neoadjuvant-only regimen (Checkmate 816) and three full perioperative strategies. The choice requires multidisciplinary discussion, and the selected immunotherapy agent must not be switched mid-course.

For fit patients with metastatic MSI-high colorectal cancer, the combination of ipilimumab and nivolumab is the preferred frontline treatment over pembrolizumab monotherapy. This is based on Phase III data showing the dual IO approach is superior. Single-agent PD-1 inhibitors are reserved for frail patients or those with autoimmune comorbidities.

The next wave in NSCLC immunotherapy involves bispecific antibodies, which are single molecules that simultaneously block both the PD-1/PD-L1 and VEGF pathways. Agents like Ivanesimab are showing superior progression-free survival compared to standard checkpoint inhibitors, establishing this dual-target approach as a leading area of development.